Detalle de: Editorial: Cannabidiol Treatment in Neurotherapeutic Interventions

Cannabidiol Treatment in Neurotherapeutic InterventionsCannabidiol, usually referred to as CBD, is the second most abundant active ingredient in cannabis, one of the oldest medicinal plants in the world (Zuardi, 2006).Although CBD was first extracted from cannabis in 1940 (Adams et al., 1940), its chemical structure was not fully characterized until 1963 (Mechoulam and Shvo, 1963).In terms of its pharmacokinetic profile, CBD is highly lipophilic, have poor oral bioavailability (as low as 6%), and is well tolerated by humans with no signs of toxicity or serious side effects and drug interactions (Millar et al., 2018;Huestis et al., 2019).Pharmacodynamically, CBD acts on over 65 molecular targets, including transient receptor potential vanilloid (TRPV) channels, serotonin (5-HT 1A ) receptors, and cannabinoid-related receptors such as G protein-coupled receptor 55 (GPR55).Interestingly, the actions of CBD on the two main endocannabinoid receptors are limited by its low affinity.At higher doses, it functions as a negative allosteric modulator for CB 1 receptors and an inverse agonist for CB 2 receptors.Indirectly, CBD also activates CB 1 receptors by inhibiting fatty acid amide hydrolase (FAAH), the enzyme that degrades anandamide (AEA), the endogenous ligand for CB 1 receptors (Britch et al., 2021).It is important to note that, unlike tetrahydrocannabinol (i.e., THC, the main psychoactive chemical in cannabis), CBD is non-addictive (Viudez-Martinez et al., 2019), which makes it an exceptional alternative to THC-derivative cannabinoid drugs.Touted as a cure-all for many health conditions and disorders (e.g., anxiety, depression, schizophrenia, PTSD), CBD has become increasingly ubiquitous in the marketplace (Brown and Winterstein, 2019).Spurred by the increasing legality of the medical use of the Cannabis sativa plant,